Analysts Set Vor Biopharma Inc. (NYSE:VOR) Target Price at $11.36

Vor Biopharma Inc. (NYSE:VOR) has been assigned a consensus rating of “Buy” from the seven ratings firms that are presently covering the stock, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $11.36.

A number of brokerages have weighed in on VOR. Robert W. Baird lowered their price objective on Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and set a $12.00 price objective on shares of Vor Biopharma in a report on Friday, September 6th. HC Wainwright reissued a “buy” rating and issued a $17.50 target price on shares of Vor Biopharma in a report on Friday, November 8th. Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Vor Biopharma in a research note on Friday, November 8th. Finally, Barclays cut their price target on shares of Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating for the company in a report on Wednesday, August 14th.

Institutional Trading of Vor Biopharma

A number of hedge funds have recently made changes to their positions in VOR. Vanguard Group Inc. increased its position in shares of Vor Biopharma by 4.0% during the first quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock worth $4,297,000 after acquiring an additional 69,436 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Vor Biopharma by 48.0% during the 2nd quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock worth $495,000 after purchasing an additional 160,642 shares during the last quarter. Exchange Traded Concepts LLC increased its holdings in Vor Biopharma by 40.8% during the 3rd quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company’s stock worth $116,000 after purchasing an additional 48,017 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Vor Biopharma by 51.4% in the 2nd quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock valued at $79,000 after purchasing an additional 27,597 shares in the last quarter. Finally, Rosalind Advisors Inc. purchased a new position in shares of Vor Biopharma during the 3rd quarter valued at approximately $54,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Trading Down 0.8 %

Shares of VOR stock opened at $0.79 on Friday. The company has a market capitalization of $54.25 million, a P/E ratio of -0.48 and a beta of -0.40. The business’s 50 day moving average is $0.78 and its two-hundred day moving average is $1.00. Vor Biopharma has a twelve month low of $0.63 and a twelve month high of $3.14.

Vor Biopharma (NYSE:VOR) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.40) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.40). As a group, equities analysts predict that Vor Biopharma will post -1.55 earnings per share for the current fiscal year.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.